Kidney Cancer

Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.

Experts present and discuss new findings from the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib vs sunitinib in renal cell carcinoma.

A panel of experts, a patient, and her caregiver discuss her renal cell carcinoma diagnosis, the prevalent treatment options, and optimal strategies for patient education.

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, offers a perspective on a clinical quandary published recently in the journal ONCOLOGY.

Data from the phase 2 KEYNOTE-B61 trial indicate that pembrolizumab plus lenvatinib’s safety profile in the first-line treatment of patients with non-clear cell renal cell carcinoma is safe and manageable.

Pembrolizumab plus axitinib also improves the overall response rate vs sunitinib alone among patients with clear cell renal cell carcinoma in the phase 3 KEYNOTE-426 trial.

Data from the phase 3 CONTACT-03 trial highlight the necessity of randomized, prospective assessment of re-challenge with checkpoint inhibitors in renal cell carcinoma, according to an expert from Dana-Farber Cancer Institute.

Lenvatinib plus pembrolizumab generates no new safety signals among patients with advanced renal cell carcinoma in the phase 3 CLEAR study.

Patients with renal cell carcinoma with variant histologies appear to benefit from treatment with a triplet regimen of cabozantinib, nivolumab, and ipilimumab.

The combination is also associated with a manageable toxicity profile in the second and subsequent treatment lines for patients with advanced renal cell carcinoma.

Santosh Rao, MD, discusses ongoing and potential future research efforts aiming to maximize the benefits that patients with kidney cancer may derive from integrative oncology treatment techniques.

Santosh Rao, MD, discusses guideline recommendations and therapeutic techniques that underscore the current integrative oncology landscape for patients with kidney cancer.

The addition of cabozantinib to nivolumab and ipilimumab also appears to improve responses in patients with advanced renal cell carcinoma in the phase 3 COSMIC-313 trial.

Chung-Han Lee, MD, PhD, and colleagues discuss the case of a patient with renal cell carcinoma, touching on optimal treatments, toxicities, and other factors.

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.

Data from the phase 3 ZIRCON trial evaluating 89Zr-DFO-girentuximab in patients with renal tumors may be practice changing, according to an expert from the University of California Los Angeles.

According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.

Pharmacy director Kirollos Hanna, PharmD, BCPS, BCOP, FACC, discusses how to navigate shared toxicities between combination immunotherapy and VEGF inhibitors for patients with renal cell carcinoma.

According to an expert from University Hospitals, oncologists should work together and look for opportunities to improve patients’ diets and exercise routines to mitigate symptoms of kidney cancer and associated treatment.

According to an expert from University Hospitals, studying pathways related to inflammation, epigenetics, and the microbiome may elucidate how patients with kidney cancer respond to anti-cancer therapy.

In the phase 3 RENOTORCH trial, frontline toripalimab plus axitinib appears to improve the overall response rate of patients with unresectable or metastatic renal cell carcinoma.

Results from a phase 2 study support additional clinical trials assessing belzutifan-based regimens for patients with advanced clear cell renal cell carcinoma.

An expert from University Hospitals touches on pain management guidelines that highlight moderate evidence in support of acupuncture, reflexology, and acupressure and massage as tools to manage general pain in patients with cancer.

Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.

ALLO-316 has some “unique features” that may make it an “attractive” treatment option for those with kidney cancer, according to an expert from The University of Texas MD Anderson Cancer Center.

An expert from University Hospitals highlights different guidelines penned by oncology organizations informing the integrative management of symptoms including anxiety and depression in patients with kidney cancer.

Massage and acupuncture represent promising integrative care strategies for managing stress and pain in patients with kidney cancer and other tumors, according to an expert from University Hospitals.

Expert panelists share their perspective on novel and combination strategies being investigated in the setting of metastatic renal cell carcinoma.

Switching focus to a second clinical scenario, key opinion leaders on metastatic renal cell carcinoma discuss the treatment landscape for favorable-risk disease.